Gelonghui November 15th | Shenzhou Cell (688520.SH) Investor Relations Activity Record Form shows that the 14-valent HPV vaccine recipients have completed the third dose, are currently in the follow-up stage, and related research and data analysis are voluntary disclosure information by the company. The company will disclose information in accordance with laws and regulations based on business progress.
神州细胞(688520.SH)：14价HPV疫苗受试者已完成第三针接种，现正处在随访阶段
Shenzhen SinoCell (688520.SH): The 14-valent HPV vaccine trial participants have completed the third dose and are now in the follow-up stage.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated